AUTHOR=Li Yong , Huang Jinpeng , Chen Xian , Ye Yongsong , Du Xiaohua , Voutsadakis Ioannis A. , Seetharam Mahesh , Zhang Haibo , Lu Min 

TITLE=Case report: Metastatic refractory undifferentiated small round-cell sarcoma successfully treated with surufatinib and camrelizumab

JOURNAL=Frontiers in Oncology

VOLUME=Volume 14 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1416241

DOI=10.3389/fonc.2024.1416241

ISSN=2234-943X

ABSTRACT=Background: Undifferentiated small round-cell sarcomas (uSRCSs) are a subgroup of sarcomas that are difficult to diagnose. Some uSRCSs have specific gene rearrangements, but others do not. Currently, there is no specific treatments for advanced uSRCSs, and its treatment is largely based on general experience with sarcomas, which A CT scan showed that the tumor achieved a partial response. As of April 2023, the patient had a progression-free survival time of 26 months.Conclusions: Surufatinib in combination with camrelizumab could be effective in the treatment of advanced uSRCSs.